Mounting adaptive immune responses requires the cell surface expression of major histocompatibility class II molecules (MHC II) loaded with antigenic peptide. However, in the absence of antigenic stimuli, the surface population of MHC II is highly dynamic and exhibits a high turnover. Several studies have focused on the regulation of MHC II, and it is now recognized that ubiquitination is one key mechanism operating in the turnover of MHC II in B cells and dendritic cells. Here, we describe how the invariant chain (Ii) can prolong the half-life of MHC II through its action on the endocytic pathway. We find that in cells expressing intermediate-to-high levels of Ii, the half-life of MHC II is increased, with MHC II accumulating in slowly-maturing endosomes. The accumulation in endosomes is not due to retention of new MHC II directed from the endoplasmatic reticulum, as also mature, not Ii associated, MHC II is preserved. We suggest that this alternative endocytic pathway induced by Ii would serve to enhance the rate, quantity and diversity of MHC II antigen presentation by concentrating MHC II into specialized compartments and reducing the need for new MHC II synthesis upon antigen encounter. Major histocompatibility class II molecules (MHC II) are present on a particular set of immune cells, typically termed antigen-presenting cells (APCs). MHC II are expressed as heterodimers composed of two non-covalently associated type I (N-terminal in lumen) transmembrane polypeptides. These highly polymorphic molecules bind short polypeptides derived from endocytosed protein antigens and present these to the T cell receptors on CD4 + T-cell clones. The a (35 kD) and b (27 kD) chains of MHC II can spontaneously associate in the endoplasmatic reticulum (ER) because of interaction sites in their transmembrane and luminal domains. However, the assembly of stable heterodimers is greatly enhanced in the presence of Invariant chain (Ii). In the ER, this type II transmembrane protein self-associates into trimers, which provide a scaffold for the assembly of three MHC II heterodimers. The MHC II interacting domains in Ii are found in the transmembrane region and the luminal domain, with the major interacting site binding into the peptide-binding groove of MHC II, thus also preventing premature binding of endogenous peptides to MHC II en route to endosomes. 1 Ii also serves a crucial function in the transport of new MHC II to the endosomes where the production and loading of antigenic peptides occurs. This is due to leucine-based sorting-motifs in the N-terminal, cytosolic tail of Ii, which can interact with adaptor proteins-1 and -2, which mediate transport from the Trans Golgi network and from the cell surface, respectively. 2 Although most textbooks describe a direct pathway for new MHC II-Ii complexes from the Trans Golgi network to endosomes, earlier studies and recent RNA interference-based studies indicate that a major pathway goes via the cell surface. [3][4][5] Upon entry into the endocytic pathway, Ii is rapidly degraded f...